---
layout: post
title: "Proposal To Withdraw Approval of MAKENA; Hearing"
date: 2026-02-05 19:00:18 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-17715
original_published: 2022-08-17 00:00:00 +0000
significance: 8.00
---

# Proposal To Withdraw Approval of MAKENA; Hearing

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** August 17, 2022 00:00 UTC
**Document Number:** 2022-17715

## Summary

The Food and Drug Administration (FDA, Agency, or we) has granted a hearing on the Center for Drug Evaluation and Research's (CDER's) proposal to withdraw approval of MAKENA (hydroxyprogesterone caproate injection, 250 milligrams (mg) per milliliter (mL), once weekly), new drug application (NDA) 021945, held by Covis Pharma Group/ Covis Pharma GmbH (Covis). This notice provides information and details regarding the hearing, including the time, date, and format of the hearing, as well as the questions to be posed to the advisory committee at the hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/08/17/2022-17715/proposal-to-withdraw-approval-of-makena-hearing)
- API: https://www.federalregister.gov/api/v1/documents/2022-17715

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
